Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 66 points (-0.4%) at 17,671 as of Monday, Jan. 12, 2015, 12:05 PM ET. The NYSE advances/declines ratio sits at 975 issues advancing vs. 1,992 declining with 175 unchanged.

The Health Care sector currently sits up 0.3% versus the S&P 500, which is down 0.8%. Top gainers within the sector include Foundation Medicine ( FMI), up 103.1%, Hologic ( HOLX), up 4.9%, Allergan ( AGN), up 1.7%, Biogen Idec ( BIIB), up 1.8% and Actavis ( ACT), up 1.4%. On the negative front, top decliners within the sector include HCA Holdings ( HCA), down 2.5%, Vertex Pharmaceuticals ( VRTX), down 2.6%, Shire ( SHPG), down 1.8%, Cigna ( CI), down 1.5% and Express Scripts ( ESRX), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. NPS Pharmaceuticals ( NPSP) is one of the companies pushing the Health Care sector higher today. As of noon trading, NPS Pharmaceuticals is up $3.46 (8.3%) to $45.38 on heavy volume. Thus far, 53.4 million shares of NPS Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $45.33-$45.50 after having opened the day at $45.46 as compared to the previous trading day's close of $41.91.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS Pharmaceuticals has a market cap of $4.6 billion and is part of the drugs industry. Shares are up 17.2% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate NPS Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates NPS Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full NPS Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AstraZeneca ( AZN) is up $1.44 (2.1%) to $70.88 on average volume. Thus far, 731,924 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $70.01-$71.05 after having opened the day at $70.75 as compared to the previous trading day's close of $69.44.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $87.2 billion and is part of the drugs industry. Shares are down 1.3% year-to-date as of the close of trading on Friday. Currently there are 3 analysts who rate AstraZeneca a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates AstraZeneca as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Sanofi ( SNY) is up $0.42 (0.9%) to $44.97 on light volume. Thus far, 666,713 shares of Sanofi exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $44.26-$45.09 after having opened the day at $44.97 as compared to the previous trading day's close of $44.55.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sanofi discovers, develops, and distributes therapeutic solutions. Sanofi has a market cap of $119.9 billion and is part of the drugs industry. Shares are down 2.3% year-to-date as of the close of trading on Friday. Currently there is 1 analyst who rates Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. Among the primary strengths of the company is its expanding profit margins over time. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null